| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S19464 R82991 |
Straub (Controls exposed to LTG) (Topiramate) (Epilepsy), 2026 | Autism spectrum disorder - ICD-10 codes: F84.x (except F84.2, F84.3) - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.51 [0.82;2.79] C excluded (control group) |
15/961 34/3,273 | 49 | 961 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S19474 R83125 |
Straub (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 | Autism spectrum disorder - ICD-10 codes: F84.x (except F84.2, F84.3) - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 0.83 [0.46;1.48] | 15/961 106/8,887 | 121 | 961 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17437 R73264 |
Madley-Dowd_SE (Topiramate) (Controls exposed to LTG), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Partial overlapping |
4.06 [1.68;9.78] C excluded (control group) |
6/71 53/2,383 | 59 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17438 R73267 |
Madley-Dowd_SE (Topiramate) (Controls unexposed, sick), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Partial overlapping | 2.79 [1.23;6.30] | 6/71 425/10,769 | 431 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17255 R72216 |
Madley-Dowd_UK (Topiramate) (Controls unexposed, sick) (Epilepsy), 2024 | Autism - ICD10 codes - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 0.68 [0.08;5.36] | -/43 78/4,075 | - | 43 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15875 R65444 |
Dreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023 | Autism spectrum disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
2.32 [1.10;4.88] C excluded (control group) |
8/290 64/5,288 | 72 | 290 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15876 R65453 |
Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 | Autism spectrum disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 1.93 [0.95;3.94] | 8/290 323/22,203 | 331 | 290 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6183 R16277 |
Wood (Topiramate), 2015 | Score >30 (CARS) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 17.00 [0.13;2166.90] C | 0/1 0/9 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.53 [0.80;2.94] | 883 | 1,366 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick) (Topiramate) (Epilepsy; 2: Topiramate) (Controls unexposed, sick; 3: Topiramate) (Controls unexposed, sick) (Epilepsy; 4: Topiramate) (Epilepsy) (Controls unexposed, sick; 5: Topiramate;
Asymetry test p-value = 0.5992 (by Egger's regression)
slope=0.0319 (0.6214); intercept=0.8243 (1.4072); t=0.5858; p=0.5992
excluded 15875, 17437, 19464